martedì, 1 dicembre 2020
Medinews
6 Marzo 2018

FDA Grants Fast Track Designation to Pamrevlumab in Locally Advanced Unresectable Pancreatic Cancer

March 2, 2018 – On March 1, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for the anti–connective tissue growth factor (CTGF) antibody pamrevlumab for the treatment of patients with locally advanced unresectable pancreatic cancer. This follows review of the phase II clinical trial evaluating pamrevlumab in combination with gemcitabine and nanoparticle albumin–bound (nab)-paclitaxel. “There are no approved treatment … (leggi tutto)

TORNA INDIETRO